Ben Westphalen

The honour of a lifetime! As a European at heart, I’m super excited (& a little proud) to announce that I will join the @EU_Commission Mission Board for Cancer to promote the mission and to help driving the #EUCancerPlan 🇪🇺❤️ research-and-innovation.ec.europa.eu/news/all-resea…

Dear Colleagues at #ASCO25 As ALWAYS, it is a pleasure for @OncoAlert 🚨 to be around to capture yet another GREAT @Uromigos discussion by @tompowles1 🇬🇧& @brian_rini 🇺🇸 Here they are lakeside discussing Final Results of IO-Based Combination in mRCC Ping OncoAlert GU Faculty…

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] @BenWestphalen et al. @Nature_NPJ Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of >295,000 cancer patients

🔬 Discover the ELCAP framework—a 3-tier guide to using Large Language Models #LLMs in clinical practice. 👉 Register now with your free ESMO account: 🔗 ow.ly/fY1m50WnyGJ

The relevance of a WIDE molecular profiling in #PDAC and #BiliaryMalignancies Our data from @Hospital_FJD presented at @myESMO #ESMOGI25 👉Targets in PDAC are identified when wide pannels are used-regardless of KRAS 🧬MTAP loss present both in PDAC and BTC #ESMOAmbassadors

🚨Happy 4th everyone! Delighted to share with the🌎our comment just published in Lancet Oncology @TheLancetOncol @TheLancet on “Bridging Classification & Treatment” 👉🏼 🧬 Tumor biology > tumor location. It’s time we evolve WHO cancer classification to match how we treat it: by…

A very important step in the right direction by the @EU_Commission which will help to improve #CancerCare in #Europe 🇪🇺

Great overview of #PrecisionMedicine in #PDAC by @EileenMOReilly at @myESMO #ESMOGI25 If you missed it, please watch it 📺 🧬NGS important, with RNA for fusions 🫶KRAS 🤞🏻MTAP 👀Claudin 18.2 🤝Molecular Tumor Board-ESMO recomendations available #ESMOAmbassadors @BenWestphalen

@BenWestphalen delivered compelling insights into diving deep into the #BRAF pathway in colorectal cancer. #ESMOGI25 By spotlighting targeted 👉🏻 approaches, he underscored how ❗️pathway-focused research opens the door to more precise, high-impact treatments!! @myESMO

Newly-released ESMO recommendations critically assess specific germline pathogenic variants in terms of cancer-related mortality and testing implications for patients and their families Read the full article in the #ESMODailyReporter 🔗 ow.ly/xpGT50W9PuY

It’s been an absolute pleasure to be part of this @ASCO @myESMO session during #ASCO25 - in order to deliver the best care to our #patients we need equitable, scalable and sustainable solutions based on solid evidence. #PrecisionMedicine @OncoAlert 🚨

TEDOPAM - maintenance randomised phase 2 vaccine trial #PDAC Induction mFFX- Folfiri vs Folfiri+ OSE2101 (TAAs) ➡️106 pts ➡️met primary endpoint of 12mth OS>50%; ➡️But control arm mOS 17 vs vaccine arm 15mths ➡️highlights benefit maintenance approaches @ASCO @OncoAlert #ASCO25

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity @OncoAlert #ASCO25 @OICR_news @pmcancercentre

In just 45 min… #TheOncoAlert5k 🏃 Come join us We leave 7am in front of the McCormick, up the lake to the Chicago river and return to the same place See you here !! #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD…

The OncoAlert🚨DAILY Newsletter at #ASCO25, REGISTER HERE 👉 OncoAlert360.com OR buff.ly/p0O1gZ8 OUT TOMORROW MORNING!!! The OncoAlert Network will be delivering a daily newsletter to oncologists worldwide during ASCO 2025 — featuring our top trial picks from…

Welcome to #ASCO25 ! On behalf of the🚨OncoAlert Network—hello from Chicago! 🌆 🔗 Sign up the Newsletter: oncoalert.m-pages.com/nhMpwe/oncoale… WE ARE ALL OncoAlert 🚨 For 7 years, we've brought you real-time updates from the biggest oncology congresses. This year, we’re back with: 🔹…

Kicking off @ASCO #ASCO25 with a molecular tumor board session meeting incredible international #PrecisionMedicine super stars ⭐️ @lungoncdoc Ryan Ngyuen Max Christopeit #PrecisionMedicine @OncoAlert 🚨

💥🚨 A tweetorial/ X'torial on the paper published today "Tissue-agnostic cancer therapies: promise, reality, and the path forward" @NatureComms @NaturePortfolio 👉The Future of Cancer Treatment is Here: Tissue-Agnostic Therapies @OncoAlert @ASCO #ASCO25 A Thread 🧵 1/15…